buildleaf smgt-glp-1 Counterfeit weight loss products claiming to contain GLP-1 smgt glp 1 ATTDX® SlimBalance

Several GLP-1 agonists have FDA approval for other indications that may overlap with BED patient populations: Semaglutide (Wegovy) and liraglutide (Saxenda) are approved for chronic weight management in adults with obesity (BMI 30) or overweight (BMI 27) with at least one weight-related comorbidity Semaglutide (Ozempic), liraglutide (Victoza), dulaglutide (Trulicity), and tirzepatide (Mounjaro) are approved for type 2 diabetes management Tirzepatide (Zepbound) is approved for chronic weight management When clinicians prescribe GLP-1 agonists for BED, this constitutes off-label use a legal and common practice in medicine when evidence suggests potential benefit and approved treatments are inadequate

The body weight-reducing effects of the GLP-1RAs in persons with T2D range between 0.3 and 6.3 kg, with the most marked effect observed with dulaglutide (17) and semaglutide (18)

PMID: 27252647

Tasali E, Mokhlesi B, Van Cauter E

Manufacturers can tailor formulations to supplement common deficiencies that GLP-1 agonist users may experience due to their altered diet

Well thats all for this week